

December 18, 2018

To,
**SINGAPORE EXCHANGE SECURITIES
TRADING LIMITED**
11 North Buona Vista Drive,
#06-07 The Metropolis Tower 2,
Singapore – 138589

Dear Sirs,

**Sub: Glenmark Pharmaceuticals receives ANDA approval for Fluocinolone Acetonide Oil, 0.01%
(Ear Drops)**

With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Glenmark Pharmaceuticals Limited

**HARISH
VINAYAK KUBER**

Digitally signed by HARISH VINAYAK KUBER
DN: c=IN, o=Personal, postalCode=400049, st=Maharashtra,
2.5.4.20=cde2956f5be913821f9f9f91026d376afdae5f5fb8838
c3a71de2e75255a782d,
serialNumber=afdac79f9832ea525179ba4771e8bfb76ef0e3c
ac491160cbf271c8084b16e4f, cn=HARISH VINAYAK KUBER
Date: 2018.12.18 09:36:14 +05'30'

**Harish Kuber
Company Secretary & Compliance Officer**

Encl: as above

Press Release

For Immediate Release

Glenmark Pharmaceuticals receives ANDA approval for Fluocinolone Acetonide Oil, 0.01% (Ear Drops)

Mumbai, India, December 18, 2018: Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Fluocinolone Acetonide Oil, 0.01% (Ear Drops), a generic version of DermOtic^{®1} Oil, 0.01% (Ear Drops), of Hill Dermaceuticals, Inc.

According to IQVIA[™] sales data for the 12 month period ending October 2018, the DermaOtic[®] Oil, 0.01% (Ear Drops) market² achieved annual sales of approximately \$18.1 million*.

Glenmark's current portfolio consists of 146 products authorized for distribution in the U.S. marketplace and 54 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

¹All brand names and trademarks are the property of their respective owners.

²Market includes brand and all available therapeutic equivalents

*IQVIA[™] National Sales Perspectives: Retail & Non-Retail, October 2018

--End--

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical organization. It is ranked among the top 75 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2018). Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is focused in the areas of oncology, dermatology and respiratory.

The company has a significant presence in the branded generics markets across emerging economies including India. Glenmark has 16 manufacturing facilities across five countries and has six R&D centers. The Generics business of Glenmark services the requirements of the US and Western European markets. The API business sells its products in over 80 countries, including the US, various countries in the EU, South America and India.

For further information, please contact:

Isha Trivedi

Glenmark, Mumbai, India

Tel: +91 22 4018 9801

Email: corpcomm@glenmarkpharma.com